Trial · NCT00575185
Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection
NCT00575185, Phase 1, Phase 2, Completed, University of Minnesota; results first posted 2015-03-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection. Trials, record NCT00575185. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00575185
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection
- NCT number
- NCT00575185
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 23 participants, actual
- Lead sponsor
- University of Minnesota
- Conditions
- Infectious Mononucleosis
- Interventions
- Valomaciclovir, placebo
- First posted
- 2007-12-18
- Last updated
- 2017-03-22
- Results first posted
- 2015-03-17
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline | 21 days | All subjects had confirmed cases of EB and will be assessed for Improvement of clinical symptoms (ie: tiredness, nausea etc)and reduction in viral burden from baseline |
| Secondary | Number of Participants Who Experienced Adverse Events During the Study Safety and Tolerability | 15 days | Assessing adverse events in participants to see if this drug causes more or less side effects |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline | 21 days | participants | NUMBER | |
| SECONDARY | Number of Participants Who Experienced Adverse Events During the Study Safety and Tolerability | 15 days | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline | Valomaciclovir | 12 | participants | ||
| Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline | Placebo | 11 | participants | ||
| Number of Participants Who Experienced Adverse Events During the Study Safety and Tolerability | Valomaciclovir | 12 | participants | ||
| Number of Participants Who Experienced Adverse Events During the Study Safety and Tolerability | Placebo | 11 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Valomaciclovir | 12 | |
| Overall Study | STARTED | Placebo | 11 | |
| Overall Study | COMPLETED | Valomaciclovir | 12 | |
| Overall Study | COMPLETED | Placebo | 11 | |
| Overall Study | NOT COMPLETED | Valomaciclovir | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Pain | Gastrointestinal disorders | Valomaciclovir | 6 | 12 | 6 |
| other | Abdominal Pain | Gastrointestinal disorders | Placebo | 5 | 11 | 5 |
| other | Headache | Nervous system disorders | Valomaciclovir | 4 | 12 | 4 |
| other | Headache | Nervous system disorders | Placebo | 5 | 11 | 5 |
| other | Nausea | Gastrointestinal disorders | Valomaciclovir | 7 | 12 | 7 |
| other | Nausea | Gastrointestinal disorders | Placebo | 1 | 11 | 1 |
| other | Vomiting | Gastrointestinal disorders | Valomaciclovir | 3 | 12 | 3 |
| other | Vomiting | Gastrointestinal disorders | Placebo | 0 | 11 | 0 |
| other | Rash | Skin and subcutaneous tissue disorders | Valomaciclovir | 2 | 12 | 2 |
| other | Rash | Skin and subcutaneous tissue disorders | Placebo | 1 | 11 | 1 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Valomaciclovir | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Valomaciclovir | 7 | 12 |
| Total, other adverse events | Placebo | 5 | 11 |
| Total, serious adverse events | Valomaciclovir | 1 | 12 |
| Total, serious adverse events | Placebo | 0 | 11 |
Source ClinicalTrials.gov
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Valomaciclovir vs Placebo: Number of Participants Who Experienced Adverse Events During the Study Safety and Tolerability | Trial comparisons |
| Valomaciclovir vs Placebo: Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline | Trial comparisons |
| Valomaciclovir vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00575185
GET https://conductscience.org/api/trials/v1/NCT00575185/registered